D.A. Davidson & Co. Crispr Therapeutics Ag Transaction History

D.A. Davidson & Co.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$70.09 - $111.29 $206,204 - $327,415	-2,942 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $39,231 - $55,763	356 Added 13.77%	2,942 $329,000
Q1 2021 May 07, 2021	BUY	$110.72 - $210.04 $286,321 - $543,163	2,586 New	2,586 $315,000
Q4 2018 Jan 29, 2019	SELL	$22.73 - $42.34 $179,021 - $333,469	-7,876 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$44.35 - $65.71 $327,081 - $484,611	-7,375 Reduced 48.36%	7,876 $349,000
Q2 2018 Aug 02, 2018	SELL	$42.62 - $73.59 $42 - $73	-1 Reduced 0.01%	15,251 $896,000
Q1 2018 May 04, 2018	SELL	$23.52 - $58.17 $11,760 - $29,085	-500 Reduced 3.17%	15,252 $697,000
Q4 2017 Feb 08, 2018	BUY	$16.95 - $23.48 $266,996 - $369,856	15,752	15,752 $370,000

483

64.1M

1.64M

1.93M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.07B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.